U.K., Sept. 9 -- The final clinical trials for a COVID-19 vaccine, being developed by AstraZeneca in partnership with Oxford University, have been paused following a participant having a suspected adverse reaction and falling ill. Despite this hiccup in the trials, it is hoped that AstraZenca and Oxford University's vaccine will be one of the first available on the market with successful phase one and phase two testing.
Adverse side effects are not unheard of in clinical trials, and Oxford University has branded this instance as "routine" and hopes that the trial will be commenced again shortly. This is the second incident to occur in the Oxford trials since it started back in April. A spokesman for Oxford University said: "In large trial...